USPTO serial 79032245
PENUMBRA IS BRAIN
Reviewed by CopyMark Law Group
Reg. 3580586Status 404
- Filing date
- Status date
- Registration date
- Feb 24, 2009
- Examiner
- SOMERVILLE, ARETHA CHARESE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with PENUMBRA IS BRAIN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biochemical preparations for scientific purposes; reagents for research | SECTION 71 - CANCELLED | — |
| 005 | Pharmaceutical preparations, namely, pharmaceutical preparations derived from living organism proteins and peptides for treatment and diagnosis of tumors, cancer, dermatological diseases, spinal cord injuries, osteoporosis, cell degeneration, allergies, endocrine diseases, hormonal imbalances, nervous diseases, diseases of the respiration system, kidney and bladder diseases, infectious diseases, gastrointestinal diseases, pain and epilepsy; pharmaceutical anti-inflammatory preparations; pharmaceutical nutriceutical preparations for the treatment of strokes, neuron damage, thrombotic diseases, tumors, cancer, heart disease including heart failure, circulation disorders, dermatological diseases, spinal cord injuries, osteoporosis, cell degeneration, allergies, endocrine diseases, hormonal imbalances, nervous diseases, diseases of the respiration system, kidney and bladder diseases, infectious diseases, gastrointestinal diseases, pain and epilepsy; blood cloning test kits comprised of medical diagnostic reagents; medical and clinical diagnostic reagents for clinical or medical laboratory use; Pharmaceutical preparations, namely, thrombolytic, fibrinolytic anti-coagulative, antithrombotical or neuroprotective substances for the treatment of blood clotting, cell protection and cell regeneration; products from biotechnological methods, namely, proteins for therapeutic and diagnostic use in the treatment and diagnosis of blood clotting disorders | SECTION 71 - CANCELLED | — |
| 010 | Laboratory and analysis apparatus for medical, pharmaceutical and laboratory tests; medical devices, namely, coated catheters, medical stents, surgical implants comprising artificial materials; membranes intended for medical use, namely, filters for dialysis, hemofiltration | SECTION 71 - CANCELLED | — |
| 041 | Educational services, namely, providing seminars, informational events and/or workshops in the field of biotechnology, pharmacology, biochemistry, molecular biology, medical procedures, product research and development of medical devices and pharmaceutical preparations, research procedures, protein design diagnostics, molecular diagnostics, proteogenomic profiling, gendiagnostics | SECTION 71 - CANCELLED | — |
| 042 | Database development for others; computer programming for others; performing chemical analyses for others; technical consultation in the field of biotechnology; licensing of intellectual property; services of a biotechnological laboratory, namely, conducting lab research for others in the field of drug research and development; pharmaceutical consulting, namely, providing pharmaceutical advice to others regarding governmental regulatory laws and practices, performing pre-clinical studies, quality control; preparation of expert opinions in the field of chemical engineering, biology, molecular biology, pharmacology, chemistry, bio-technology, bio-chemistry, product research and development of medical devices and pharmaceutical preparations, and molecular diagnostic services of a bio-chemist, namely, product research and development services for others in the area of gene expression analysis, namely, proteogenomic profiling, DNA-sequencing, drug target development and identifying, designing and analyzing therapeutic proteins; diagnostic services in the field of molecular science, comparative genome analysis, DNA-arrays including DNA-microarrays, creation of nucleic acid libraries, screening of nucleic acid libraries; performance of pre-clinical studies, namely, conducting and managing pre-clinical trials and studies of pharmaceutical, bio-technology and health care products; bio-chemical and biotechnological research and development for others, namely, bio-technological research and development regarding medical disease diagnosis and pharmacology, namely, prenatal diagnostic and identification of hereditary factors leading to diseases, identification of genes involved in the formation of cancer, identification of target molecules for cancer treatment, scientific research on and development of medical diagnostic equipment and pharmaceutical preparations and products for the treatment of tumors, cancer, dermatological diseases, spinal cord injuries, osteoporosis, cell degeneration, allergies, endocrine diseases, hormonal imbalances, nervous diseases, diseases of the respiration system, kidney and bladder diseases, infectious diseases, gastrointestinal diseases, pain and epilepsy; scientific and technical consulting for others in the field of medical science and drug research, namely, identifying, designing, and developing drugs, specifically, therapeutic proteins, gene expression analysis, namely, proteogenomic profiling, DNA-sequencing, drug target development, identification and design; medical science research services for others, namely, prenatal diagnostics, molecular diagnostics, comparative genome analysis, DNA-arrays including DNA-microarrays, creating and screening of nucleic acid libraries, identifying hereditary factors leading to diseases, identifying genes involved in the formation of cancer, identification of target molecules for cancer treatment | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Paion Deutschland GmbH
- Other trademarks owned by Paion Deutschland GmbH
- Other trademarks owned by Paion Deutschland GmbH
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 041
- Other trademarks in Class 042
- Similar marks named PENUMBRA IS BRAIN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 14, 2017 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Feb 24, 2017 | DENC | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED | — |
| Feb 24, 2017 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| May 27, 2016 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| May 27, 2016 | INPC | INVALIDATION PROCESSED | — |
| May 25, 2016 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Sep 25, 2015 | C71T | CANCELLED SECTION 71 | — |
| Dec 13, 2013 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jan 11, 2013 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| May 29, 2009 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| May 29, 2009 | FIMP | FINAL DISPOSITION PROCESSED | — |
| May 24, 2009 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Feb 24, 2009 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 15, 2009 | TMBN | TTAB RELEASE CASE TO TRADEMARKS | — |
| Jan 15, 2009 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Jan 15, 2009 | OP.D | OPPOSITION DISMISSED NO. 999999 | — |
| May 23, 2008 | RFNP | REFUSAL PROCESSED BY IB | — |
| Apr 18, 2008 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| Apr 17, 2008 | OPNS | OPPOSITION NOTICE (IB REFUSAL) SENT TO IB | — |
| Apr 17, 2008 | OPNC | OPPOSITION NOTICE (IB REFUSAL) CREATED | — |
| Dec 20, 2007 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Dec 18, 2007 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 28, 2007 | NPUB | NOTICE OF PUBLICATION | — |
| Nov 14, 2007 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Nov 14, 2007 | ALIE | ASSIGNED TO LIE | — |
| Oct 10, 2007 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 27, 2007 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Jul 27, 2007 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 26, 2007 | ALIE | ASSIGNED TO LIE | — |
| Jul 10, 2007 | PAPER RECEIVED | — | |
| Jun 12, 2007 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 1, 2007 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 10, 2007 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 10, 2007 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 29, 2006 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 28, 2006 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 22, 2006 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 22, 2006 | NWAP | NEW APPLICATION ENTERED | — |
| Dec 21, 2006 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |